title: Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus.
abstract: Lymphocytic choriomeningitis virus (LCMV) is a murine arenavirus whose glycoprotein consists of a transmembrane subunit (GP-2) and a receptor-binding subunit (GP-1). LCMV-neutralizing antibodies (nAbs) are directed against a single site on GP-1 and occur 1 month after the infection of cytotoxic-T-lymphocyte (CTL) deficient mice. In wild-type mice, however, CTLs control early infection, and weak nAb titers emerge very late (after 70 to 150 days) if at all. Production of recombinant GP-1 in native conformation enabled us to study the emergence of GP-1-binding antibodies directed against the neutralizing epitope. By combining binding and neutralization assays, we correlated the development of binding antibodies versus nAbs in wild-type and CTL-deficient mice after infection with different LCMV doses. We found that wild-type mice developed GP-1-specific antibodies already by day 8 after exposure to high but not low doses, demonstrating that naive GP-1-specific B cells were infrequent. Furthermore, the induced antibodies bound to the neutralizing GP-1 epitope but failed to neutralize the virus and therefore were of low affinity. In CTL-deficient mice, where massive viremia quickly levels initial differences in viral load, low and high doses induced low-affinity non-neutralizing GP-1-binding antibodies with kinetics similar to high-dose-infected wild-type mice. Only in CTL-deficient mice, however, the GP-1-specific antibodies developed into nAbs within 1 month. We conclude that LCMV uses a dual strategy to evade nAb responses in wild-type mice. First, LCMV exploits a "hole" in the murine B-cell repertoire, which provides only a small and narrow initial pool of low-affinity GP-1-specific B cells. Second, affinity maturation of the available low-affinity non-neutralizing antibodies is impaired.
authors: Institute of Experimental Immunology, University Hospital Zürich, Schmelzbergstrasse 12, CH-8091 Zürich, Switzerland. bruno.eschli@bluewin.ch
authors: Bruno
authors: B
authors: Eschli
authors: Raphaël M
authors: RM
authors: Zellweger
authors: Alexander
authors: A
authors: Wepf
authors: Karl S
authors: KS
authors: Lang
authors: Katharina
authors: K
authors: Quirin
authors: Jacqueline
authors: J
authors: Weber
authors: Rolf M
authors: RM
authors: Zinkernagel
authors: Hans
authors: H
authors: Hengartner
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D000914:Antibodies, Viral / Q000737:chemistry; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D000939:Epitopes / Q000737:chemistry*; D006023:Glycoproteins / Q000737:chemistry; D008216:Lymphocytic Choriomeningitis / Q000517:prevention & control / Q000821:virology; D008217:Lymphocytic choriomeningitis virus / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D008968:Molecular Conformation; D009698:Nucleoproteins / Q000737:chemistry; D017434:Protein Structure, Tertiary; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D000939:Epitopes; D006023:Glycoproteins; D009698:Nucleoproteins
references: Proc Natl Acad Sci U S A. 2003 May 13;100(10):6015-20
references: 12730366
references: J Virol. 2006 Jun;80(12):5897-907
references: 16731928
references: Virology. 2003 Dec 20;317(2):191-6
references: 14698659
references: J Clin Invest. 2004 Oct;114(7):988-93
references: 15467838
references: J Immunol. 1969 May;102(5):1128-35
references: 5770437
references: Nature. 1972 Aug 11;238(5363):335-7
references: 4561841
references: J Immunol. 1978 Oct;121(4):1262-9
references: 308960
references: Virology. 1981 Aug;113(1):73-85
references: 6267791
references: Virology. 1983 Oct 15;130(1):247-51
references: 6636539
references: Virology. 1986 Sep;153(2):168-78
references: 2426862
references: J Immunol. 1987 Apr 1;138(7):2278-81
references: 2435794
references: J Virol. 1987 Jun;61(6):1867-74
references: 3494855
references: Virology. 1988 May;164(1):30-8
references: 2452517
references: J Exp Med. 1988 May 1;167(5):1749-54
references: 2966846
references: Virology. 1989 Aug;171(2):417-26
references: 2474891
references: Virology. 1990 Jul;177(1):175-83
references: 2141203
references: Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):8252-6
references: 1910175
references: J Virol Methods. 1991 Jun;33(1-2):191-8
references: 1939506
references: J Virol. 1992 Jun;66(6):3661-8
references: 1583725
references: Eur J Immunol. 1992 Jul;22(7):1803-12
references: 1623925
references: J Virol. 1992 Dec;66(12):7270-81
references: 1331520
references: Eur J Immunol. 1993 Jul;23(7):1540-5
references: 8325330
references: J Immunol. 1993 Nov 15;151(10):5408-15
references: 7693811
references: Nature. 1994 May 5;369(6475):31-7
references: 8164737
references: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2749-54
references: 10688894
references: Annu Rev Biochem. 2000;69:531-69
references: 10966468
references: J Virol. 2001 Jan;75(2):1061-4
references: 11134321
references: J Exp Med. 2001 Feb 5;193(3):297-305
references: 11157050
references: J Cell Biol. 2001 Oct 15;155(2):301-10
references: 11604425
references: BMC Microbiol. 2001;1:1
references: 11208257
references: J Virol. 1995 Feb;69(2):1059-70
references: 7815484
references: Mol Phylogenet Evol. 1997 Dec;8(3):301-16
references: 9417890
references: J Virol. 1998 Mar;72(3):2253-8
references: 9499083
references: J Exp Med. 1998 May 4;187(9):1383-93
references: 9565631
references: Science. 1998 Dec 11;282(5396):2079-81
references: 9851928
references: J Immunol. 1999 Apr 15;162(8):4536-41
references: 10201992
references: J Virol. 2005 Mar;79(6):3822-30
references: 15731275
references: Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8
references: 16219699
references: Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12883-8
references: 14569006